Car-T Experience

Strategic Research Insights (SRI) possesses focused expertise in CAR-T therapy within the oncology and hematology landscape. SRI has conducted comprehensive market research and strategic consulting specifically tailored to CAR-T treatments, including studies on multiple myeloma and other hematologic malignancies. SRI’s capabilities include demand estimation and forecasting for indication changes and new launches, detailed sales force effectiveness studies, and extensive qualitative research with key stakeholders such as clinicians, patients, and payers.

This expertise enables clients to effectively design launch strategies, optimize commercial resources, and understand patient and provider decision-making dynamics within the evolving CAR-T therapy field. SRI integrates these insights to support clients in navigating the complexities of CAR-T commercialization and maximizing product impact.